KR20070109975A - 항체의 농축 방법 및 이의 치료용 생성물 - Google Patents

항체의 농축 방법 및 이의 치료용 생성물 Download PDF

Info

Publication number
KR20070109975A
KR20070109975A KR1020077007862A KR20077007862A KR20070109975A KR 20070109975 A KR20070109975 A KR 20070109975A KR 1020077007862 A KR1020077007862 A KR 1020077007862A KR 20077007862 A KR20077007862 A KR 20077007862A KR 20070109975 A KR20070109975 A KR 20070109975A
Authority
KR
South Korea
Prior art keywords
antibody
ultrafiltration
diafiltration
concentration
buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020077007862A
Other languages
English (en)
Korean (ko)
Inventor
찰스 매튜 윈터
Original Assignee
제넨테크, 인크.
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35996499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20070109975(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 제넨테크, 인크., 노파르티스 아게 filed Critical 제넨테크, 인크.
Priority to KR1020127030933A priority Critical patent/KR101528970B1/ko
Publication of KR20070109975A publication Critical patent/KR20070109975A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B01D61/146—Ultrafiltration comprising multiple ultrafiltration steps
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/16—Feed pretreatment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/04—Specific process operations in the feed stream; Feed pretreatment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/16—Flow or flux control
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicinal Preparation (AREA)
KR1020077007862A 2004-09-09 2005-09-08 항체의 농축 방법 및 이의 치료용 생성물 Ceased KR20070109975A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020127030933A KR101528970B1 (ko) 2004-09-09 2005-09-08 항체의 농축 방법 및 이의 치료용 생성물

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60909204P 2004-09-09 2004-09-09
US60/609,092 2004-09-09
US11/220,362 2005-09-06
US11/220,362 US20060051347A1 (en) 2004-09-09 2005-09-06 Process for concentration of antibodies and therapeutic products thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020127030933A Division KR101528970B1 (ko) 2004-09-09 2005-09-08 항체의 농축 방법 및 이의 치료용 생성물

Publications (1)

Publication Number Publication Date
KR20070109975A true KR20070109975A (ko) 2007-11-15

Family

ID=35996499

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020077007862A Ceased KR20070109975A (ko) 2004-09-09 2005-09-08 항체의 농축 방법 및 이의 치료용 생성물
KR1020127030933A Expired - Lifetime KR101528970B1 (ko) 2004-09-09 2005-09-08 항체의 농축 방법 및 이의 치료용 생성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020127030933A Expired - Lifetime KR101528970B1 (ko) 2004-09-09 2005-09-08 항체의 농축 방법 및 이의 치료용 생성물

Country Status (32)

Country Link
US (6) US20060051347A1 (cg-RX-API-DMAC7.html)
EP (5) EP2292636B9 (cg-RX-API-DMAC7.html)
JP (2) JP5210633B2 (cg-RX-API-DMAC7.html)
KR (2) KR20070109975A (cg-RX-API-DMAC7.html)
CN (3) CN101056885B (cg-RX-API-DMAC7.html)
AR (1) AR050641A1 (cg-RX-API-DMAC7.html)
AU (1) AU2005285243C1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0515649B8 (cg-RX-API-DMAC7.html)
CA (1) CA2577317C (cg-RX-API-DMAC7.html)
DK (5) DK3805248T5 (cg-RX-API-DMAC7.html)
EC (1) ECSP077282A (cg-RX-API-DMAC7.html)
ES (5) ES2968070T3 (cg-RX-API-DMAC7.html)
FI (4) FI4108259T3 (cg-RX-API-DMAC7.html)
GT (1) GT200500254A (cg-RX-API-DMAC7.html)
HU (4) HUE061899T2 (cg-RX-API-DMAC7.html)
IL (2) IL181372A (cg-RX-API-DMAC7.html)
LT (4) LT4108259T (cg-RX-API-DMAC7.html)
MA (1) MA28991B1 (cg-RX-API-DMAC7.html)
MX (2) MX2007002812A (cg-RX-API-DMAC7.html)
MY (2) MY150549A (cg-RX-API-DMAC7.html)
NO (1) NO333660B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ553239A (cg-RX-API-DMAC7.html)
PE (1) PE20060816A1 (cg-RX-API-DMAC7.html)
PL (5) PL2292636T3 (cg-RX-API-DMAC7.html)
PT (5) PT2292636T (cg-RX-API-DMAC7.html)
RU (1) RU2390524C2 (cg-RX-API-DMAC7.html)
SG (1) SG177161A1 (cg-RX-API-DMAC7.html)
SI (5) SI4104859T1 (cg-RX-API-DMAC7.html)
TN (1) TNSN07069A1 (cg-RX-API-DMAC7.html)
TW (1) TWI372630B (cg-RX-API-DMAC7.html)
WO (1) WO2006031560A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200701626B (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190038921A (ko) * 2016-08-17 2019-04-09 베링거 인겔하임 인터내셔날 게엠베하 생체 분자를 함유하는 고농축 액상 제형의 제조 방법
KR20190046872A (ko) * 2016-08-16 2019-05-07 젠자임 코포레이션 재조합 치료 단백질을 포함하는 유체의 처리 방법 및 상기 유체의 용도
WO2019132418A1 (ko) * 2017-12-27 2019-07-04 ㈜셀트리온 투석 여과 방법

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
EP1324776B2 (en) * 2000-10-12 2018-03-21 Genentech, Inc. Reduced-viscosity concentrated protein formulations
JP4869064B2 (ja) 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド 高濃度抗体及びタンパク質製剤
NZ548871A (en) 2004-01-30 2009-06-26 Shire Pharmaceuticals Ireland Use of arylsulfatase A for treating metachromatic leukodystrophy
PT1765294E (pt) 2004-05-12 2008-12-30 Baxter Healthcare Sa Microesferas de ácido nucleico, sua produção e entrega
JP2007537288A (ja) 2004-05-12 2007-12-20 バクスター インターナショナル インコーポレイテッド オリゴヌクレオチド含有マイクロスフェア、１型糖尿病を処置する医薬の製造のための、その使用
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
MX2007015476A (es) 2005-06-14 2008-02-25 Amgen Inc Formulaciones de proteina autoamortiguadoras.
EP2583744A1 (en) * 2006-03-31 2013-04-24 Genencor International, Inc. Permeate product of tangential flow filtration process
BRPI0709737A2 (pt) 2006-04-04 2011-07-26 Zymenex As processo para concentraÇço de um polipeptÍdeo
CA2681752A1 (en) 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human 1l-12 antibodies
KR101215740B1 (ko) * 2007-07-17 2012-12-27 루드비히-막시밀리안스-우니버지테트 뮌헨 가변적 접선류 여과
JP5205470B2 (ja) * 2007-11-29 2013-06-05 エフ．ホフマン−ラ ロシュ アーゲー 免疫グロブリン凝集物
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
TW200938221A (en) * 2007-11-30 2009-09-16 Abbott Lab Protein formulations and methods of making same
AU2009236305B2 (en) * 2008-04-15 2014-04-10 Grifols Therapeutics Inc. Two-stage ultrafiltration/diafiltration
RU2010151414A (ru) * 2008-05-15 2012-06-20 В.Хэлт Л.П. (Bs) Способ получения фракций молока, обогащенных секреторными иммуноглобулинами
CA2744510A1 (en) * 2008-12-09 2010-06-17 F.Hoffmann-La Roche Ag Method for obtaining an excipient-free antibody solution
EP2393579B1 (en) * 2009-01-21 2017-03-08 Smartflow Technologies, Inc. Optimization of separation for viscous suspensions
BRPI1006519A2 (pt) * 2009-03-06 2016-08-09 Genentech Inc formulação de anticorpos
US9586180B2 (en) * 2009-03-24 2017-03-07 Wyeth Llc Membrane evaporation for generating highly concentrated protein therapeutics
US8546548B2 (en) * 2009-05-27 2013-10-01 Baxter International Inc. Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
SI2483304T1 (sl) * 2009-09-29 2016-08-31 F. Hoffmann-La Roche Ag Predfiltracijsko naravnavanje pufrskih snovi za močno koncentriran imunoglobulinski pripravek
ES2604103T3 (es) * 2009-10-01 2017-03-03 F. Hoffmann-La Roche Ag Filtración final de una preparación de inmunoglobulina en múltiples pasos
WO2011095543A1 (en) 2010-02-04 2011-08-11 Csl Behring Ag Immunoglobulin preparation
PH12012501742A1 (en) 2010-03-01 2022-03-21 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
EP2729566B1 (en) 2011-07-08 2017-03-15 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a
JP6363017B2 (ja) 2011-09-01 2018-07-25 中外製薬株式会社 限外ろ過によって高度に濃縮された抗体を含む組成物を調製するための方法
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US20150361131A1 (en) * 2012-12-28 2015-12-17 Novo Nordisk A/S High temperature dead end antibody filtration
JP6427502B2 (ja) 2013-01-09 2018-11-21 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド アリールスルファターゼａの精製方法
DE102013001628A1 (de) 2013-01-30 2014-07-31 Fresenius Medical Care Deutschland Gmbh Verfahren zur Bereitstellung eines Konzentrats
IL296603B2 (en) 2014-05-13 2024-04-01 Amgen Inc Process control systems and methods for use with filters and filtration processes
US10207225B2 (en) 2014-06-16 2019-02-19 Emd Millipore Corporation Single-pass filtration systems and processes
US10550148B2 (en) * 2014-06-16 2020-02-04 Emd Millipore Corporation Methods for increasing the capacity of flow-through processes
EP2957335B1 (en) * 2014-06-16 2020-05-27 EMD Millipore Corporation Single-pass filtration systems and processes
EP4144434B1 (en) * 2014-06-16 2024-04-17 EMD Millipore Corporation Single-pass filtration systems and processes
KR102199262B1 (ko) 2014-06-25 2021-01-06 이엠디 밀리포어 코포레이션 밀집한 나권형 필터 엘리먼트, 모듈 및 시스템
KR102235952B1 (ko) 2014-08-29 2021-04-07 이엠디 밀리포어 코포레이션 잔류물의 재순환을 이용한 싱글 패스 접선 유동 여과 시스템 및 접선 유동 여과 시스템
CN105592913B (zh) 2014-08-29 2018-04-03 Emd 密理博公司 用于使用单程切向流过滤系统和具有渗余物的再循环的切向流过滤系统过滤液体的方法
BR112017008125B1 (pt) 2014-10-23 2023-11-21 Amgen Inc. Método para a redução da viscosidade de formulações farmacêuticas, formulações farmacêuticas, método de preparação de um pó liofilizado, pó liofilizado e método para reconstituição de um pó liofilizado
WO2016087569A1 (en) 2014-12-03 2016-06-09 Csl Behring Ag Pharmaceutical product with increased stability comprising immunoglobulins
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
KR20180037056A (ko) * 2015-09-22 2018-04-10 화이자 인코포레이티드 치료학적 단백질 제형의 제조 방법 및 이러한 방법에 의해 생산된 항체 제형
CA3023486C (en) 2016-06-09 2022-03-29 Emd Millipore Corporation Radial-path filter elements, systems and methods of using same
CA3040899A1 (en) 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
CN107952280A (zh) * 2017-11-28 2018-04-24 安徽东方帝维生物制品股份有限公司 一种兽用疫苗无菌超滤浓缩装置及方法
EP3774894A1 (en) * 2018-04-12 2021-02-17 Amgen Inc. Methods for making stable protein compositions
TWI846694B (zh) 2018-05-04 2024-07-01 美商健臻公司 具有過濾系統的灌注式生物反應器
MA53272A (fr) * 2018-08-10 2021-11-17 Amgen Inc Procédé de préparation d'une formulation pharmaceutique d'anticorps
EP3837273B1 (en) * 2018-08-14 2025-09-24 Bristol-Myers Squibb Company Improved protein recovery
TWI871300B (zh) * 2019-01-28 2025-02-01 美商安進公司 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
AU2020223376A1 (en) * 2019-02-15 2021-07-22 Just - Evotec Biologics, Inc. Automated biomanufacturing systems, facilities, and processes
EP3791395B1 (en) * 2019-07-31 2021-08-11 Catalent U.K. Swindon Zydis Limited Density flow meter for pharmaceutical formulation dosing
CN111018968B (zh) * 2019-12-16 2021-07-27 兴盟生物医药(苏州)有限公司 一种通过超滤浓缩制备高浓度抗体制剂的方法
JP7338527B2 (ja) * 2020-03-19 2023-09-05 東レ株式会社 体液検体中のアレルゲン特異的ＩｇＥ抗体の検出方法
CN111944046B (zh) * 2020-08-28 2021-04-09 江苏荃信生物医药有限公司 高浓度、低粘度抗人il-23单克隆抗体溶液的制备方法
KR20230080460A (ko) * 2020-10-05 2023-06-07 브리스톨-마이어스 스큅 컴퍼니 단백질을 농축시키는 방법
CA3199735A1 (en) 2020-11-23 2022-05-27 Chris Klopp Filtration systems,components and methods
EP4304764A1 (en) * 2021-03-08 2024-01-17 Boehringer Ingelheim International GmbH Systems and methods for single pass counter current diafiltration
CN114014929B (zh) * 2021-11-04 2022-07-19 江苏荃信生物医药股份有限公司 一种抗人白介素-33单克隆抗体浓缩溶液的制备方法
EP4482956A1 (en) 2022-02-25 2025-01-01 Amgen Inc. Methods of preparing high concentration liquid drug substances
CN115261193A (zh) * 2022-05-31 2022-11-01 利穗科技(苏州)有限公司 一种生物制品浓缩系统及其工艺
CA3261698A1 (en) * 2022-07-12 2024-01-18 Beigene Switzerland Gmbh METHODS FOR PREPARING A HIGHLY CONCENTRATED PD1 ANTIBODY SOLUTION BY ULTRAFILTRATION/DIAFILTRATION (UF/DF)
CN115873064A (zh) * 2022-09-27 2023-03-31 英脉生物医药(杭州)有限公司 高浓度蛋白样品的制备装置及方法
WO2024224337A1 (en) * 2023-04-25 2024-10-31 Enzene Biosciences Limited In line cleaning in place process for alternating tangential flow filter
US12030959B1 (en) 2023-07-05 2024-07-09 Genentech, Inc. Anti-IgE antibody therapy for multiple food allergies
CA3237624A1 (en) 2023-07-28 2025-04-24 Genentech, Inc. NEW USES FOR OMALIZUMAB
WO2025101602A1 (en) 2023-11-07 2025-05-15 Amgen Inc. Methods of analyzing amino acid content of a therapeutic protein

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5625616B2 (cg-RX-API-DMAC7.html) 1973-10-08 1981-06-13
FR2459619B1 (fr) 1979-06-26 1983-07-29 Agronomique Inst Nat Rech Procede pour l'obtention a partir de lactoserum, d'un produit enrichi en alpha-lactalbumine et applications dudit procede
US4362661A (en) 1979-08-09 1982-12-07 Teijin Limited Immunoglobulin composition having a high monomer content, and process for production thereof
US4374763A (en) 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IN161706B (cg-RX-API-DMAC7.html) * 1983-10-05 1988-01-16 Solco Basel Ag
US4786501A (en) * 1985-07-15 1988-11-22 International Minerals & Chemical Corp. Cylindrical implants for the controlled release of growth hormones
US4756696A (en) 1985-12-06 1988-07-12 Amp Incorporated Solder joint inspection feature for surface mount connectors
GB8628104D0 (en) * 1986-11-25 1986-12-31 Connaught Lab Pasteurization of immunoglobin solutions
JPS6485829A (en) 1987-09-29 1989-03-30 Aisin Aw Co Transmission for four-wheel drive vehicle
JPH01268646A (ja) 1988-04-20 1989-10-26 Meiji Milk Prod Co Ltd 抗腫瘍剤
GB2218703B (en) 1988-05-10 1992-10-28 Sumitomo Chemical Co Human monoclonal antibody to p.aeruginosa: its production and use
US4897465A (en) 1988-10-12 1990-01-30 Abbott Laboratories Enrichment and concentration of proteins by ultrafiltration
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
JPH04502914A (ja) 1988-12-15 1992-05-28 セントユール，インコーポレイテッド 免疫グロブリンを可溶化するための塩基性アミノ酸の使用
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5177194A (en) * 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
NL9001650A (nl) 1990-07-19 1992-02-17 Ver Coop Melkind Werkwijze voor de bereiding van een melkeiwit-isolaat.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5256294A (en) 1990-09-17 1993-10-26 Genentech, Inc. Tangential flow filtration process and apparatus
JP2916947B2 (ja) 1990-11-28 1999-07-05 興和株式会社 Ｃｐｂ―ｉの安定化方法及び製剤組成物
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
JP2907603B2 (ja) * 1991-09-09 1999-06-21 雪印乳業株式会社 新規生理活性ペプチド、該活性ペプチドを有効成分とする胃酸分泌抑制剤、抗潰瘍剤及び飲食品
US6270757B1 (en) 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5707678A (en) 1995-04-12 1998-01-13 Galagen Inc. Method for microfiltration of milk or colostral whey
AU5632296A (en) 1995-04-27 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
PT2275119E (pt) 1995-07-27 2013-11-21 Genentech Inc Formulação de proteína liofilizada isotónica estável
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
DE19543737A1 (de) 1995-11-24 1997-05-28 Hoechst Ag Verfahren zur Ultrafiltration von Peptide oder Proteine enthaltender biologischer Matrices
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
KR100236393B1 (ko) 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
GB9610992D0 (en) * 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
KR20010030665A (ko) 1997-09-22 2001-04-16 세프라겐 코포레이션 유장 단백질의 순차적 분리법 및 그의 제제
RU2140287C1 (ru) * 1998-08-25 1999-10-27 Государственное унитарное предприятие "Иммунопрепарат" Способ получения альбумина
AU6405899A (en) 1998-10-26 2000-05-15 Galagen, Inc. Soy and immunoglobulin compositions
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
WO2001003515A1 (en) 1999-07-07 2001-01-18 New Zealand Co-Operative Dairy Company Limited Method of obtaining protein isolates and concentrates from colostrum
CA2477857C (en) 1999-10-04 2012-04-10 Chiron Corporation Stabilized liquid polypeptide-containing pharmaceutical compositions
JP5485489B2 (ja) * 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
EP1324776B2 (en) 2000-10-12 2018-03-21 Genentech, Inc. Reduced-viscosity concentrated protein formulations
ES2184594B1 (es) 2001-01-17 2004-01-01 Probitas Pharma Sa Procedimiento para la produccion de gammaglobulina g humana inactivada de virus.
ES2338218T3 (es) 2001-07-25 2010-05-05 Facet Biotech Corporation Formulacion farmacologica liofilizada estable de anticuerpos igg daclizumab.
US20030138417A1 (en) 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies
WO2003042344A2 (en) * 2001-11-13 2003-05-22 Genentech, Inc. Apo2 ligand/trail formulations
ES2311094T3 (es) 2002-02-27 2009-02-01 Immunex Corporation Composicion estabilizada de tnfr-fc que comprende arginina.
AU2003251592A1 (en) * 2002-06-21 2004-01-06 Biogen Idec Inc. Buffered formulations for concentrating antibodies and methods of use thereof
JP4500683B2 (ja) * 2002-11-01 2010-07-14 バイエル・ヘルスケア・エルエルシー 巨大分子濃縮方法
GB0229444D0 (en) 2002-12-18 2003-01-22 Royal Free Hampstead Nhs Trust Diagnostic method and assay kit
CA2516836A1 (en) * 2003-02-24 2004-09-10 Gtc Biotherapeutics, Inc. Methods of tangential flow filtration and an apparatus therefore
JP4869064B2 (ja) 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド 高濃度抗体及びタンパク質製剤
JP2008500959A (ja) 2004-01-30 2008-01-17 スオメン プナイネン リスティ ヴェリパルヴェル ウイルスについて安全な免疫グロブリンの製造方法
US20080247991A1 (en) 2004-02-26 2008-10-09 Trout Bernhardt L Solution Additives For the Attenuation of Protein Aggregation
US8471757B2 (en) 2004-08-19 2013-06-25 Electronic Navigation Research Institute, An Independent Administrative Institution Device using dielectric lens
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JP6044754B2 (ja) 2012-01-19 2016-12-14 株式会社ジェイテクト クラッチプレートおよびその製造方法
WO2019035815A1 (en) 2017-08-16 2019-02-21 O&M Halyard International Unlimited Company METHOD AND SYSTEM FOR FASTENING ATTACHES IN A METHOD FOR MANUFACTURING FACIAL MASKS

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190046872A (ko) * 2016-08-16 2019-05-07 젠자임 코포레이션 재조합 치료 단백질을 포함하는 유체의 처리 방법 및 상기 유체의 용도
US11884703B2 (en) 2016-08-16 2024-01-30 Genzyme Corporation Methods of processing a fluid including a recombinant therapeutic protein and use thereof
KR20190038921A (ko) * 2016-08-17 2019-04-09 베링거 인겔하임 인터내셔날 게엠베하 생체 분자를 함유하는 고농축 액상 제형의 제조 방법
WO2019132418A1 (ko) * 2017-12-27 2019-07-04 ㈜셀트리온 투석 여과 방법

Also Published As

Publication number Publication date
ES2968070T3 (es) 2024-05-07
FI3805248T3 (fi) 2023-04-21
SI4104859T1 (sl) 2024-08-30
NO333660B1 (no) 2013-08-05
LT4104859T (lt) 2024-07-10
AR050641A1 (es) 2006-11-08
EP1786830A2 (en) 2007-05-23
JP2008512473A (ja) 2008-04-24
SI1786830T1 (sl) 2015-03-31
SG177161A1 (en) 2012-01-30
US20070237762A1 (en) 2007-10-11
AU2005285243A1 (en) 2006-03-23
EP1786830B1 (en) 2014-11-12
HK1101249A1 (en) 2007-10-12
FI2292636T3 (fi) 2024-01-12
TNSN07069A1 (en) 2008-06-02
US20140370003A1 (en) 2014-12-18
SI3805248T1 (sl) 2023-05-31
ES2975166T3 (es) 2024-07-03
US10370456B2 (en) 2019-08-06
IL181372A0 (en) 2007-07-04
PL1786830T3 (pl) 2015-05-29
ES2942574T3 (es) 2023-06-02
EP4108259B1 (en) 2024-01-03
CN104961797A (zh) 2015-10-07
MY162525A (en) 2017-06-15
US12371510B2 (en) 2025-07-29
JP2012097086A (ja) 2012-05-24
BRPI0515649B8 (pt) 2021-11-03
PT3805248T (pt) 2023-04-05
KR101528970B1 (ko) 2015-06-15
ES2528541T3 (es) 2015-02-10
DK3805248T5 (da) 2023-04-24
US20060051347A1 (en) 2006-03-09
AU2005285243C1 (en) 2012-10-25
CN104961797B (zh) 2020-12-25
EP3805248B1 (en) 2023-01-18
KR20120135530A (ko) 2012-12-14
LT2292636T (lt) 2024-01-10
RU2007110534A (ru) 2008-10-20
FI4108259T3 (fi) 2024-09-10
SI2292636T1 (sl) 2024-02-29
NO20071432L (no) 2007-03-16
PE20060816A1 (es) 2006-09-02
NZ553239A (en) 2009-11-27
EP4108259A1 (en) 2022-12-28
AU2005285243B2 (en) 2012-03-08
ECSP077282A (es) 2007-03-29
WO2006031560A2 (en) 2006-03-23
ZA200701626B (en) 2008-10-29
US20090214522A1 (en) 2009-08-27
PT4104859T (pt) 2024-07-02
US11767370B2 (en) 2023-09-26
PL4104859T3 (pl) 2024-08-26
EP2292636A2 (en) 2011-03-09
CA2577317A1 (en) 2006-03-23
TW200612989A (en) 2006-05-01
BRPI0515649A (pt) 2008-07-29
DK1786830T3 (en) 2015-01-19
HUE061899T2 (hu) 2023-08-28
EP2292636B1 (en) 2023-10-18
TWI372630B (en) 2012-09-21
WO2006031560A3 (en) 2006-08-24
LT4108259T (lt) 2024-04-10
CN101056885B (zh) 2015-08-26
FI4104859T3 (fi) 2024-07-16
CN101056885A (zh) 2007-10-17
LT3805248T (lt) 2023-04-25
EP3805248A2 (en) 2021-04-14
GT200500254A (es) 2006-08-02
MX2007002812A (es) 2007-05-16
DK4104859T3 (da) 2024-07-08
DK4108259T3 (da) 2024-03-11
MX342788B (es) 2016-10-12
CN102911268A (zh) 2013-02-06
EP2292636B9 (en) 2024-01-03
PL3805248T3 (pl) 2023-05-22
IL181372A (en) 2012-01-31
JP5426641B2 (ja) 2014-02-26
HUE067662T2 (hu) 2024-11-28
KR101528970B9 (ko) 2022-12-09
PL4108259T3 (pl) 2024-05-13
IL216851A0 (en) 2012-01-31
HK1215869A1 (zh) 2016-09-23
MY150549A (en) 2014-01-30
CA2577317C (en) 2016-04-26
PT1786830E (pt) 2015-02-05
ES2983099T3 (es) 2024-10-22
BRPI0515649B1 (pt) 2021-10-13
SI4108259T1 (sl) 2024-04-30
DK3805248T3 (da) 2023-04-03
HUE067296T2 (hu) 2024-10-28
JP5210633B2 (ja) 2013-06-12
PT4108259T (pt) 2024-03-07
EP4104859A1 (en) 2022-12-21
EP2292636A3 (en) 2013-05-01
HUE065025T2 (hu) 2024-04-28
PL2292636T3 (pl) 2024-03-11
US20230074486A1 (en) 2023-03-09
EP3805248A3 (en) 2021-07-14
DK2292636T3 (da) 2024-01-15
RU2390524C2 (ru) 2010-05-27
PT2292636T (pt) 2024-01-09
US20210095050A1 (en) 2021-04-01
EP4104859B1 (en) 2024-04-17
MA28991B1 (fr) 2007-11-01

Similar Documents

Publication Publication Date Title
US11767370B2 (en) Process for concentration of antibodies and therapeutic products thereof
HK40047421A (en) Process for concentration of antibodies and therapeutic products thereof
HK40047421B (en) Process for concentration of antibodies and therapeutic products thereof
HK1101249B (en) Process for concentration of antibodies and therapeutic products thereof
HK1155186A (en) Process for concentration of antibodies and therapeutic products thereof
HK40084343B (en) Process for concentration of antibodies and therapeutic products thereof
HK40083042A (en) Process for concentration of antibodies and therapeutic products thereof
HK40084343A (en) Process for concentration of antibodies and therapeutic products thereof
HK1155186B (en) Process for concentration of antibodies and therapeutic products thereof
HK40083042B (en) Process for concentration of antibodies and therapeutic products thereof
HK1215869B (zh) 濃縮抗體的方法及其治療性產品
HK1178178A (en) Process for concentration of antibodies and therapeutic products thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070406

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20100908

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20120726

Patent event code: PE09021S01D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20121126

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20130329

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20120726

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20130701

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20130329

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2013101004864

Request date: 20130701

J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20130701

Effective date: 20141014

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20141014

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20130701

Decision date: 20141014

Appeal identifier: 2013101004864

J121 Written withdrawal of request for trial
PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20141113

PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20141113

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2013101004864

Request date: 20130701

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20141014

WITB Written withdrawal of application